Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.
What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Read More

Overview

Feature Articles

Latest Multiple Myeloma News and Research

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

First cell-based gene therapy approved by the FDA for treating multiple myeloma

First cell-based gene therapy approved by the FDA for treating multiple myeloma

New blood test makes it easier to follow the progression of multiple myeloma

New blood test makes it easier to follow the progression of multiple myeloma

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

Underrepresentation in genomic databases may affect therapy selection for minority patients

Underrepresentation in genomic databases may affect therapy selection for minority patients

Novel cancer-fighting gene therapy enters phase I clinical trial

Novel cancer-fighting gene therapy enters phase I clinical trial

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

Studies reveal the promise of newly engineered bispecific antibodies against tumor cells

Studies reveal the promise of newly engineered bispecific antibodies against tumor cells

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Immunomodulatory drugs improve the success rate of cancer therapies

Immunomodulatory drugs improve the success rate of cancer therapies

Study reveals mechanisms behind sensitivity of multiple myeloma cells to EZH2 inhibition

Study reveals mechanisms behind sensitivity of multiple myeloma cells to EZH2 inhibition

Study provides new insights into the mechanism of bone marrow tissue

Study provides new insights into the mechanism of bone marrow tissue

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

P2 COVID-19 study shows no material safety differences between opaganib and control arms

P2 COVID-19 study shows no material safety differences between opaganib and control arms